viewClinigen Group PLC

Clinigen Group agrees cancer drug supply deal

The company said the agreement with US life sciences group Iovance Biotherapeutics offers the chance to "revitalise" its Proleukin product

Clinigen Group PLC -
Proleukin will be used in clinical trials aimed at creating a new cancer immunotherapies

Clinigen Group PLC (LON:CLIN) has taken a “first significant step” to revitalise its Proleukin drug by agreeing to supply the product to an American life sciences company developing exciting new cancer immunotherapies.

Iovance Biotherapeutics is carrying out pivotal studies of its tumour infiltrating lymphocytes (TIL) technology on head, neck and lung patients with advanced forms of the killer disease.

Proleukin, currently used to treat liver and skin cancer, is part of the TIL therapy treatment regimen being assessed.

As such, it will be made available by Clinigen in bulk supply over a two-year period so Iovance has uninterrupted access for its clinical trials.

Chief executive Shaun Chilton said: “Proleukin is the only approved IL-2 in the US and Europe that is currently being used in TIL therapy development and is an inherent component of these programs. This is a product that is involved in over 80 clinical trials in the US alone, which presents other similar opportunities for us to pursue.”

Quick facts: Clinigen Group PLC

Price: 700 GBX

Market: AIM
Market Cap: £930.29 m


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Antibe Therapeutics releases data from company’s Phase II placebo-controlled...

Antibe Therapeutics (CVE: ATE) CEO Dan Legault joined Steve Darling from Proactive Vancouver with new results from the company’s analysis of primary and secondary data from ATB-346’s recent placebo-controlled efficacy trial. Legault shares the data with Proactive and he also maps out the...

14 hours, 11 minutes ago

2 min read